Fresenius SE & Co. KGaA · XETR:FRE

Fresenius SE & Co. KGaA — Non-Deal Roadshow (August 2019)

43 slides from Fresenius SE & Co. KGaA's roadshow presentation, Aug 28, 2019

  1. Slide 1: Roadshow Helsinki

    Roadshow Helsinki Helsinki, 28 August 2019 Frankfurt stock exchange: FRE │ US ADR program: FSNUY │ www.fresenius.com/investors

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive

  3. Slide 3: A Global Leader In HealthCare Products And Services

    A Global Leader In HealthCare Products And Services ~€33.5 bn in Sales Global presence in (as of Dec. 31, 2018) 100+ countries Total Shareholder Return: 10-year CAGR: ~15% Strong portfolio 288,000+ employees of products (30% of sales) worldwide and services (70% of sales) (as of June 30, 2019) Roads

  4. Slide 4: Strong and Balanced Health Care Portfolio

    Strong and Balanced Health Care Portfolio Ownership: ~31% Ownership: 100% Ownership: 100% Ownership: 77% Dialysis Products Hospital Supplies Hospital Operation Projects and Services for Health Care Services Hospitals • Dialysis services • IV drugs • Acute care • Post-acute care • Hemodialysis produc

  5. Slide 5: Total Shareholder Return – CAGR, Rounded

    Total Shareholder Return – CAGR, Rounded 10 years 15 years 20 years 15% 14% 13% 12% 10% 9% 8% 8% 7% 6% 6% 4% DAX S&P 500 Fresenius MSCI World Fresenius DAX S&P 500 Fresenius MSCI World Fresenius DAX S&P 500 MSCI World Fresenius Fresenius Health Care Health Care Health Care Source: Bloomberg; dividen

  6. Slide 6: Fresenius Medical Care: Global Dialysis Market Leader

    Fresenius Medical Care: Global Dialysis Market Leader • The world’s leading provider of dialysis products Market Dynamics and services treating more than 339,000 patients1 in 3,996 clinics1 Global Dialysis Market 2018: • Provide highest standard of product quality and • ~€71 bn • ~6% patient growth

  7. Slide 7: Fresenius Kabi: A Leading Global Hospital Supplier

    Fresenius Kabi: A Leading Global Hospital Supplier • Comprehensive product portfolio for critically and Market Dynamics chronically ill patients • Strong Emerging Markets presence Global Addressable Market 2018: • Leading market positions in four product • ~€81 bn segments Growth Drivers: • Patent e

  8. Slide 8: Fresenius Helios: Europe's Largest Private Hospital Operator Helios Germany

    Fresenius Helios: Europe’s Largest Private Hospital Operator Helios Germany • ~5%1 share in German acute care hospital Market Dynamics market • Organic growth based on growing number of German Acute Care Hospital Market: admissions and reimbursement rate increases • ~€102 bn2 • Ranks as quality lead

  9. Slide 9: Fresenius Helios: Europe's Largest Private Hospital Operator Helios Spain

    Fresenius Helios: Europe’s Largest Private Hospital Operator Helios Spain • ~€3.0 bn sales in 2018 Market Dynamics • ~12%1 share in Spanish private hospital market Spanish Private Hospital Market: • Market leader in size and quality with excellent • ~€14 bn2 growth prospects Growth Drivers: • Broad

  10. Slide 10: Fresenius Vamed: Leading Global Hospital Projects and Services Specialist

    Fresenius Vamed: Leading Global Hospital Projects and Services Specialist • Manages hospital construction/expansion Market Dynamics projects and provides services for health care facilities worldwide Growth Drivers: • Offers project development, planning, turnkey • Emerging Market demand for buildin

  11. Slide 11: Capital deployment centers on sustainable long-term value creation

    Fresenius Group: Capital deployment centers on sustainable long-term value creation Re- Fuel organic growth with low-risk high- investments in return investments own business Short-term focus on small bolt-on Strategic acquisitions; long-term rigorous pursuit of acquisitions inorganic growth traject

  12. Slide 12: Healthy Growth Targets 2020 - 2023

    Fresenius Group: Healthy Growth Targets 2020 - 2023 Growing Markets with High Marketing of existing Attractive markets Entry Barriers value chain Strengthening and Attractive Product Pipeline Market consolidation extension of value chain Entry into attractive Development of post- Synergies biosimila

  13. Slide 13: Healthy Growth Targets 2020 – 2023 (CAGRs)

    Fresenius Group: Healthy Growth Targets 2020 – 2023 (CAGRs) Organic sales growth 4 – 7% (plus ~1% small to mid- size acquisitions) Organic net income1 growth 5 – 9% (plus ~1% small to mid- size acquisitions) 1 Net income attributable to shareholders of Fresenius SE & Co. KGaA Before special items Ro

  14. Slide 14: Financial Review Q2/19

    Financial Review Q2/19 Roadshow Helsinki 2019 © Fresenius SE & Co. KGaA Investor Relations 14

  15. Slide 15: Q2/19 Highlights

    Q2/19 Highlights • Good organic sales growth across all business segments • Growth investments well on track • Fresenius Kabi: first biosimilar launched; continued excellent growth in Emerging Markets • Fresenius Helios: strong organic sales growth in Germany; acquisition of Cliníca Medellin in Colo

  16. Slide 16: Fresenius Kabi: Update

    Fresenius Kabi: Update IV Generics in North America • Conclusion of de-stocking during Q2/19 • Low single-digit price erosion in our base product portfolio • Intensified competition in certain molecules • Drug shortages: 36 end of Q2/19, unchanged from Q1/19; but fewer and less pronounced shortages

  17. Slide 17: Fresenius Kabi: Update

    Fresenius Kabi: Update Biosimilars Transfusion/Cell Therapy business • Successful launch of Idacio® in Germany, • Carve-out successfully completed UK, Hungary, NL and Portugal • Final phase of evaluation of strategic • Roll-out of Idacio® in other EU countries options well on track Clinical Nutritio

  18. Slide 18: Fresenius Helios: Update

    Fresenius Helios: Update Helios Germany Further progress of investment Smart.Helios initiatives • Establishment of digital platform for rehab • FY target to hire 1,000 additional nursing aftercare of chronically ill patients staff already accomplished in H1/19; further • Acquisition of software prov

  19. Slide 19: Fresenius Helios: Update

    Fresenius Helios: Update Helios Spain Expansion in Spain Expansion in Latin America • Seville site expansion – additional 30 • Opportunistic market entry strategy beds, 2 additional surgery rooms, more progresses outpatient services; total investment of • Successful entry into Colombian market ~€20

  20. Slide 20: Fresenius Group: Q2/19 Key Financials

    Fresenius Group: Q2/19 Key Financials €m Q2/191 IFRS 16 special Q2/19 Δ YoY cc1,2 effect items reported Sales 8,779 -18 - 8,761 6% EBIT 1,081 37 0 1,118 -7% Net interest -122 -58 1 -179 14% Income taxes -219 5 1 -213 9% Net income3 480 -9 0 471 0% Balance sheet total 59,342 5,587 - 64,929 Operating

  21. Slide 21: Fresenius Group: Q2/19 Business Segment Growth

    Fresenius Group: Q2/19 Business Segment Growth Organic sales growth1 EBIT growth (cc)1 +4% -17% +4% +4% +5% -6% +27% +67% +5% -7% 1 On a comparable basis: Q2/18 adjusted for divestitures of Care Coordination activities at FMC; Q2/19 adjusted for IFRS 16 effect. All figures before special items Roads

  22. Slide 22: Fresenius Kabi: Q2/19 Regional Highlights (1/2)

    Fresenius Kabi: Q2/19 Regional Highlights (1/2) North America Europe • -1% organic growth • 1% organic growth • Conclusion of de-stocking during Q2/19 • Continued strong growth of enteral nutrition business • More competition for certain molecules • Product partnering business weighed on • Easing of

  23. Slide 23: Fresenius Kabi: Q2/19 Regional Highlights (2/2)

    Fresenius Kabi: Q2/19 Regional Highlights (2/2) Emerging Markets China: • 16% organic sales growth Asia-Pacific ex China: • 12% organic sales growth • Continued positive momentum Latin America/Africa: Total Emerging Markets • 13% organic sales growth FY/19 outlook increased: Clearly double-digit org

  24. Slide 24: Fresenius Kabi: Q2 & H1/19 EBIT Growth

    Fresenius Kabi: Q2 & H1/19 EBIT Growth €m Q2/19 Δ YoY cc H1/19 Δ YoY cc North America 233 0% 478 2% Margin 40.7% 60 bps 40.0% 120 bps Europe 79 -10% 166 -4% Margin 13.8% -200 bps 14.5% -100 bps Asia-Pacific/Latin 113 20% 217 19% America/Africa Margin 20.7% 120 bps 20.6% 130 bps Corporate and Corpora

  25. Slide 25: Fresenius Helios: Q2/19 Highlights

    Fresenius Helios: Q2/19 Highlights Helios Germany Helios Spain • Strong organic sales growth of 5% with a • Solid organic sales growth of 4% despite good case mix Easter being in Q2/19 • Continued good progress with preparatory • Excellent EBIT margin of 14.6% in H1/19 structural activities • Hot su

  26. Slide 26: Fresenius Helios: Q2 & H1/19 Key Financials

    Fresenius Helios: Q2 & H1/19 Key Financials €m Q2/19 Δ YoY H1/19 Δ YoY Total sales 2,349 0%/6%1 4,660 0%/5%1 Thereof Helios Germany 1,506 -3%/5%1 2,991 -4%/3%1 Thereof Helios Spain 842 6% 1,668 7% Total EBIT2 274 -6%/-4%1 540 -5%/-4%1 Margin 11.7% -80 bps 11.6% -60 bps Thereof Helios Germany 154 -8%

  27. Slide 27: Fresenius Vamed

    Fresenius Vamed • Strong H1/19 with 29% organic sales €m Q2/19 Δ YoY H1/19 Δ YoY growth • Vamed accelerates high-end service Total sales 467 76% 907 76% provision to Helios Germany and Spain Thereof organic sales 27%1 29%1 Service business 344 106% 676 109% 35%1 38%1 Project business 123 24% 231 21%

  28. Slide 28: Fresenius Group: Cash Flow

    Fresenius Group: Cash Flow Operating CF1 Capex (net) Free Cash Flow1,2 €m Q2/19 LTM Margin Q2/19 LTM Margin Q2/19 LTM Margin 201 13.7% -165 -9.8% 36 3.9% 197 6.5% -76 -4.8% 121 1.7%3 -42 4.7% -5 -1.7% -47 3.0% Corporate/Other -33 n.a. -16 n.a. -49 n.a. Excl. FMC 433 9.4%4 -262 -6.9% 171 2.5%4 1,023

  29. Slide 29: Fresenius Group: 2019 Financial Outlook by Business Segment

    Fresenius Group: 2019 Financial Outlook by Business Segment FY/18 H1/19 FY/191 €m (except otherwise stated) Base Actual FY/19e1 New Sales growth (org) 6,544 4% 3% - 6% EBIT growth (cc) 1,1392 6% 3% - 6% Sales growth (org) 8,993 4% 2% - 5% EBIT growth 1,052 -5% -5% to -2% Sales growth (org) 1,688 29%

  30. Slide 30: Fresenius Group: 2019 Financial Guidance

    Fresenius Group: 2019 Financial Guidance €m FY/18 H1/19 FY/19e2 (except otherwise stated) Base1 Actual2 FY/19e2 New Sales growth (cc) 33,009 6% 3% - 6% 4% - 7% Net income3 1,872 0% ~0% growth (cc) 1 Before special items and after adjustments 2 Excluding transaction-related expenses, revaluations of

  31. Slide 31: Attachments

    Attachments Roadshow Helsinki 2019 © Fresenius SE & Co. KGaA Investor Relations 31

  32. Slide 32: Group: Leverage Ratio

    Fresenius Group: Leverage Ratio Net Debt/EBITDA target 2019 4,00 4.0 Around the upper-end of self-imposed target 3.5 3,50 corridor of 2.5 – 3.0 x3 2 3.22 3.21 2 3.09 2.98 3,00 3.0 3.00 2.97 2.98 2.84 2.80 2.75 2.71 2.67 2.65 2,50 2.5 2.55 2.53 2.33 2,00 1 2011 2012 2013 2014 2015 2016 Q1 Q2 Q3 Q4 Q1

  33. Slide 33: Fresenius Kabi: Organic Sales Growth by Regions

    Fresenius Kabi: Organic Sales Growth by Regions Δ YoY Δ YoY €m Q2/19 organic H1/19 organic North America 573 -1% 1,196 -1% Europe 572 1% 1,145 2% Asia-Pacific/Latin 546 14% 1,051 14% America/Africa Asia-Pacific 374 15% 715 13% Latin America/Africa 172 13% 336 15% Total sales 1,691 4% 3,392 4% Roadsh

  34. Slide 34: Fresenius Kabi: Organic Sales Growth by Product Segment

    Fresenius Kabi: Organic Sales Growth by Product Segment Δ YoY Δ YoY €m Q2/19 organic H1/19 organic IV Drugs 711 1% 1,456 0% Infusion Therapy 206 -1% 413 2% Clinical Nutrition 471 11% 924 9% Medical Devices/ 303 7% 599 9% Transfusion Technology Total sales 1,691 4% 3,392 4% Roadshow Helsinki 2019 © F

  35. Slide 35: Fresenius Helios: Key Metrics

    Fresenius Helios: Key Metrics H1/19 FY/18 Δ No. of hospitals Helios Germany 86 86 0% - Acute care hospitals 83 83 0% No. of hospitals Helios Spain 50 47 6% (Hospitals) No. of beds Helios Germany 29,356 29,329 0% - Acute care hospitals 28,829 28,802 0% No. of beds Helios Spain 7,126 7,019 2% (Hospita

  36. Slide 36: Attachments

    Attachments Roadshow Helsinki 2019 © Fresenius SE & Co. KGaA Investor Relations 36

  37. Slide 37: FY/18 base for Fresenius Group Guidance FY/19

    FY/18 base for Fresenius Group Guidance FY/19 €m Sales reported 33,530 Divestitures of Care Coordination activities at FMC (H1/18) -521 Sales basis for growth rates 33,009 Net income reported 2,027 Transaction Costs, Akorn, Biosimilars 25 Bridge Financing Costs Akorn 12 Revaluations of Biosimilars c

  38. Slide 38: FY/18 base for Fresenius Medical Care Outlook FY/19

    FY/18 base for Fresenius Medical Care Outlook FY/19 €m Sales reported 16,547 Divestitures of Care Coordination activities at FMC (H1/18) -521 Sales basis for growth rates 16,026 Net income reported 1,982 Impact of FCPA related charge 28 Gain related to divestitures of Care Coordination activities -6

  39. Slide 39: FY/18 base for Fresenius Kabi Outlook FY/19

    FY/18 base for Fresenius Kabi Outlook FY/19 €m Sales basis for growth rates 6,544 Transaction Costs Akorn, Biosimilars 34 Revaluations of Biosimilars contingent liabililties 7 EBIT (before special items = base for Kabi guidance) 1,139 The special items are reported in the Group Corporate/Other segme

  40. Slide 40: IFRS 16: Profit and Loss - Implications

    IFRS 16: Profit and Loss - Implications €m Expected IFRS 16 effect on 2019 Sales - ~€0.1 bn (discontinuation of sale-leaseback transactions at FMC NA) EBITDA + ~€1.0 bn (fewer rent expenses) Depreciation and amortization - ~€0.9 bn (additional depreciation) EBIT + ~€0.1 bn Interest - ~€0.2 bn (addit

  41. Slide 41: IFRS 16: Balance Sheet

    IFRS 16: Balance Sheet €m Expected IFRS 16 effect on 2019 Right-of-use-asset ~€5.2 bn Lease liability ~€5.5 bn Equity ~-€0.3 bn Leverage + ~30-40 bps Leases have to be recognized as a right-of-use-asset and corresponding liability Roadshow Helsinki 2019 © Fresenius SE & Co. KGaA Investor Relations 4

  42. Slide 42: 26th Consecutive Dividend Increase

    Fresenius Group: 26th Consecutive Dividend Increase CAGR +16% 0.75 0.80 0.62 0.55 0.32 0.37 0.42 0.44 € 0.29 0.23 0.25 0.22 0.19 0.16 0.02 '93 '05 '06 '07 '08 '09 '10 '11 '12 '13 '14 '15 '16 '17 '18 Dividend growth aligned to EPS growth Pay-out ratio: 24% Roadshow Helsinki 2019 © Fresenius SE & Co.

  43. Slide 43: Financial Calendar / Contact

    Financial Calendar / Contact Financial Calendar 29 October 2019 Results Q3/19 Please note that these dates could be subject to change. Contact Investor Relations Fresenius SE & Co. KGaA phone: +49 6172 608-2485 e-mail: ir-fre@fresenius.com For further information and current news: www.fresenius.com

Fresenius SE & Co. KGaA — Non-Deal Roadshow (August 2019) on 6ix